Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.

Le CT, Sanvito F, Yang C, Eldred BSC, Raymond C, Prins TJ, Fisher A, Li T, Liau LM, Chong RA, Nghiemphu PL, Cloughesy TF, Lai A, Ellingson BM

Open source

DOI: 10.1093/noajnl/vdag089
Published: 2026 Jan-Dec
Container: Neuro-oncology advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/noajnl/vdag089,
  title = {Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.},
  author = {Le CT and Sanvito F and Yang C and Eldred BSC and Raymond C and Prins TJ and Fisher A and Li T and Liau LM and Chong RA and Nghiemphu PL and Cloughesy TF and Lai A and Ellingson BM},
  year = {2026},
  journal = {Neuro-oncology advances},
  doi = {10.1093/noajnl/vdag089},
  url = {https://doi.org/10.1093/noajnl/vdag089}
}

RIS

TY  - JOUR
TI  - Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.
AU  - Le CT
AU  - Sanvito F
AU  - Yang C
AU  - Eldred BSC
AU  - Raymond C
AU  - Prins TJ
AU  - Fisher A
AU  - Li T
AU  - Liau LM
AU  - Chong RA
AU  - Nghiemphu PL
AU  - Cloughesy TF
AU  - Lai A
AU  - Ellingson BM
PY  - 2026
JO  - Neuro-oncology advances
DO  - 10.1093/noajnl/vdag089
UR  - https://doi.org/10.1093/noajnl/vdag089
ER  -

APA

CT, L., F, S., C, Y., BSC, E., C, R., TJ, P., A, F., T, L., LM, L., RA, C., PL, N., TF, C., A, L., & BM, E. (2026). Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.. Neuro-oncology advances. https://doi.org/10.1093/noajnl/vdag089

Source records

pubmed · retrieved 2026-09-26T00:33:09.533Z